Stay updated on Crenezumab Long-Term Safety in Alzheimer's Clinical Trial
Sign up to get notified when there's something new on the Crenezumab Long-Term Safety in Alzheimer's Clinical Trial page.

Latest updates to the Crenezumab Long-Term Safety in Alzheimer's Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov page footer now displays revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check7 days agoChange DetectedThe page now presents the completed Phase II long-term safety extension study of crenezumab for people with mild to moderate Alzheimer’s disease. It includes study details, participant criteria, locations, outcome measures, record dates, and a study protocol document.SummaryDifference80%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check42 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating that access to the study record is blocked and offering a Home link.SummaryDifference0.5%

Stay in the know with updates to Crenezumab Long-Term Safety in Alzheimer's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Crenezumab Long-Term Safety in Alzheimer's Clinical Trial page.